Impact of HSD11B1 polymorphisms on BMI and components of the metabolic syndrome in patients receiving psychotropic treatments

Lina Quteineh, Frederik Vandenberghe, Nuria Saigi Morgui, Aurélie Delacrétaz, Eva Choong, Mehdi Gholam-Rezaee, Pierre J. Magistretti, Guido Bondolfi, Armin Von Gunten, Martin A. Preisig, Enrique Castelao, Peter Vollenweider, Gérard Waeber, Murielle Bochud, Zoltán Kutalik, Philippe O. Conus, Chin Bin Eap

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


Background Metabolic syndrome (MetS) associated with psychiatric disorders and psychotropic treatments represents a major health issue. 11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) is an enzyme that catalyzes tissue regeneration of active cortisol from cortisone. Elevated enzymatic activity of 11β-HSD1 may lead to the development of MetS. Methods We investigated the association between seven HSD11B1 gene (encoding 11β-HSD1) polymorphisms and BMI and MetS components in a psychiatric sample treated with potential weight gain-inducing psychotropic drugs (n=478). The polymorphisms that survived Bonferroni correction were analyzed in two independent psychiatric samples (n R1 =168, n R2 =188) and in several large population-based samples (n 1 =5338; n 2 =123 865; n 3 >100 000). Results HSD11B1 rs846910-A, rs375319-A, and rs4844488-G allele carriers were found to be associated with lower BMI, waist circumference, and diastolic blood pressure compared with the reference genotype (P corrected
Original languageEnglish (US)
Pages (from-to)246-258
Number of pages13
JournalPharmacogenetics and Genomics
Issue number5
StatePublished - Mar 9 2015

Bibliographical note

KAUST Repository Item: Exported on 2020-10-01
Acknowledgements: This work has been funded in part by the Swiss National Research Foundation (CBE and PC: 324730_144064). C.B.E. has received research support from Takeda and from the Roche Organ Transplantation Research Foundation in the past 3 years. M.B. is supported by the Swiss School of Public Health Plus (SSPH+). P.V. and G.W. received an unrestricted grant from GlaxoSmithKline to build the CoLaus study. The CoLaus/PsyCoLaus study received financial contributions from GlaxoSmithKline, the Faculty of Biology and Medicine of Lausanne, the Swiss National Science Foundation (105993, 118308, 122661, 139468). Z.K. received support from the Leenaards Foundation and the Swiss National Science Foundation (31003A-143914).

ASJC Scopus subject areas

  • Genetics
  • Molecular Medicine
  • Molecular Biology
  • Genetics(clinical)


Dive into the research topics of 'Impact of HSD11B1 polymorphisms on BMI and components of the metabolic syndrome in patients receiving psychotropic treatments'. Together they form a unique fingerprint.

Cite this